Erratum to “siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion” [Translational Research 214C (2019) 105-120](S1931524419301689)(10.1016/j.trsl.2019.08.005)

Worapol Ngamcherdtrakul, Wassana Yantasee

Research output: Contribution to journalComment/debatepeer-review

Abstract

The publisher regrets that the author information was incorrect in the footnote. This has been corrected for the online version. The correct information is “Worapol Ngamcherdtrakul, PhD, is a scientist at PDX Pharmaceuticals. Dr. Ngamcherdtrakul's research is focused on developing nanoparticles for cancer-targeted co-delivery of drug and siRNA and developing topical formulations of a nanotechnology for skin diseases. He also leads the cancer immunotherapy program at PDX Pharmaceuticals”. The publisher would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)77
Number of pages1
JournalTranslational Research
Volume217
DOIs
StatePublished - Mar 2020

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Biochemistry, medical
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Erratum to “siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion” [Translational Research 214C (2019) 105-120](S1931524419301689)(10.1016/j.trsl.2019.08.005)'. Together they form a unique fingerprint.

Cite this